All In Biotech

Free tool

FAERS Monitor: Egrifta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 022505 or its brand name (Egrifta, Tesamorelin Acetate). Reports on generic versions are filed under their own applications.

Reports

1,692

Serious

345

20% of reports

Hospitalization

132

Death reported

32

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue297
  • incorrect dose administered164
  • injection site pain160
  • drug ineffective130
  • product preparation issue122
  • arthralgia113
  • injection site bruising99
  • weight increased99
  • therapeutic product effect incomplete86
  • injection site pruritus83
  • wrong technique in product usage process79
  • pain in extremity75
  • fatigue65
  • peripheral swelling62
  • pruritus54

Reports by year received

View as table
YearReports
20131
20162
20191
2020143
2021171
2022203
2023348
2024341
2025233
2026249

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,467 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product preparation issueSignal122235.6198.227,745
injection site bruisingSignal9915.412.81,326
injection site pruritusSignal8315.412.51,107
therapeutic product effect incompleteSignal8615.012.21,116
product dose omission issueSignal29712.611.33,192
incorrect dose administeredSignal1648.97.71,160
injection site painSignal1606.55.6748
weight increasedSignal995.54.5363
peripheral swellingSignal625.03.9196
wrong technique in product usage processSignal794.83.9240
arthralgiaSignal1133.42.8191
pain in extremitySignal753.22.5110
pruritus541.71.317
drug ineffective1301.21.06
fatigue651.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.